The company has shown its revolutionary technology can deliver life-changing therapies. Now, it's about whether CRISPR ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...

Shares of CRISPR Therapeutics (NASDAQ:CRSP) can't seem to catch a break, now down close to 8% year to date and more than 80% ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

CRISPR Therapeutics’ partner Vertex reported that more than 65 treatment centers have been activated for the gene therapy ...

CRISPR Therapeutics (NasdaqGM:CRSP) recently announced its Q1 2025 earnings, reporting a 71% year-over-year revenue increase to $0.9 million, but also a wider net loss of $136 million. The basic and ...

Gene editing is no longer a mere idea. CRISPR Therapeutics has proven it can be done. But, the best is yet to come. Lam Research's chipmaking equipment might be expensive. It's going to be ...

Chardan Capital analyst Geulah Livshits maintained CRISPR Therapeutics with a Buy rating and lowered the price target from ...

The average brokerage recommendation (ABR) for CRISPR Therapeutics (CRSP) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...